UroGen Pharma (URGN) Return on Assets: 2017-2025
Historic Return on Assets for UroGen Pharma (URGN) over the last 8 years, with Sep 2025 value amounting to -0.84%.
- UroGen Pharma's Return on Assets fell 44.00% to -0.84% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.84%, marking a year-over-year decrease of 44.00%. This contributed to the annual value of -0.55% for FY2024, which is 10.00% up from last year.
- According to the latest figures from Q3 2025, UroGen Pharma's Return on Assets is -0.84%, which was down 23.13% from -0.68% recorded in Q2 2025.
- UroGen Pharma's Return on Assets' 5-year high stood at -0.40% during Q3 2024, with a 5-year trough of -1.12% in Q1 2021.
- In the last 3 years, UroGen Pharma's Return on Assets had a median value of -0.55% in 2024 and averaged -0.65%.
- In the last 5 years, UroGen Pharma's Return on Assets soared by 58bps in 2024 and then plummeted by 44bps in 2025.
- Quarterly analysis of 5 years shows UroGen Pharma's Return on Assets stood at -0.87% in 2021, then grew by 4bps to -0.83% in 2022, then increased by 28bps to -0.55% in 2023, then climbed by 12bps to -0.43% in 2024, then slumped by 44bps to -0.84% in 2025.
- Its Return on Assets was -0.84% in Q3 2025, compared to -0.68% in Q2 2025 and -0.52% in Q1 2025.